Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mebufotenin benzoate- Atai Beckley

Next Previous
Drug Profile

Mebufotenin benzoate- Atai Beckley

Alternative Names: 5-MeO-DMT - Atai Beckley; 5-Methoxy-N-N-Dimethyltryptamine - Atai Beckley; BPL-002; BPL-003

Latest Information Update: 20 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beckley Psytech
  • Developer Atai Beckley
  • Class Analgesics; Antidepressants; Behavioural disorder therapies; Dimethylamines; Ethylamines; Indoles; Methyl ethers; Mood stabilisers; Small molecules; Tryptamines
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism; Treatment-resistant depressive disorder

Most Recent Events

  • 08 Apr 2026 Updated efficacy results from a phase II trial in Treatment resistant depressive disorder released by Atai Beckley
  • 17 Mar 2026 Efficacy and adverse event data from a phase IIa trial in Treatment resistant depressive disorder released by Atai Beckley
  • 03 Mar 2026 atai Life Sciences anticipates submission of end-of-phase 2 meeting request to the US FDA in the third quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top